345 A multicenter, randomized study of two schedules of paclitaxel (PTX) in patients with advanced breast cancer (ABC)-Reference-Cited by-同舟云学术

345 A multicenter, randomized study of two schedules of paclitaxel (PTX) in patients with advanced breast cancer (ABC)

Published:1995-11 Issue: Volume:31 Page:S75
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Peretz T.,Sulkes A.,Chollet P.,Gelmon K.,Paridaens R.,Gorbonuva V.,Catimel G.,Kuhnle H.,ten Bokkel Huinink W.,Khayat D.,Dittrich C.,Klaassen U.,Bergh J.,Wilking N.,Nabholtz J.M.,Calabresi F.,Tubiana-Hulin M.,Chazard M.,Gallant G.,Diergarten K.,Westberg R.,Bogaert J.,Renard J.,Weil C.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Comparison of Neutropenia and Peripheral Neuropathy Condition as an Impact of 3-hours and 24-hour Paclitaxel Infusion of Paclitaxel-Carboplatin Chemotherapy on Ovarian Cancer Patients;Pain medicine;2019-07-15

2. Short versus long duration infusions of paclitaxel for any advanced adenocarcinoma;Cochrane Database of Systematic Reviews;2011-05-11

3. A phase 2 study of weekly albumin-bound paclitaxel (Abraxane®) given as a two-hour infusion;Cancer Chemotherapy and Pharmacology;2011-04-03

4. Paclitaxel;Profiles of Drug Substances, Excipients and Related Methodology;2009

5. Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840;Journal of Clinical Oncology;2008-04-01